×
Hero Background

Paronychia treatment Companies

ID: MRFR/Pharma/1184-HCR
80 Pages
Kinjoll Dey
October 2025

Companies specifically dedicated to paronychia treatment may not be widespread, as this condition is typically managed by healthcare professionals using a combination of general wound care and, in some cases, prescription medications. However, companies producing relevant pharmaceuticals or products for wound care and infection management may be involved

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Paronychia treatment Market

Paronychia Treatment Market

 


Latest Paronychia Treatment Companies Updates:


Bausch Health expands Jublia reach: In October 2023, Jublia, their topical solution for paronychia, received marketing authorization in Canada, expanding its availability beyond the US and Europe.


Moberg Pharma strengthens MEA presence: Their agreement with Mundipharma in November 2020 grants them wider distribution of their topical nail disorder treatments throughout the Middle East and Africa.


FDA approval for dabrafenib/trametinib: In June 2022, the FDA approved this combination therapy for treating a rare form of paronychia related to BRAF gene mutations, offering hope for patients with limited treatment options.


List of Paronychia treatment Key companies in the market:



  • GlaxoSmithKline plc

  • Perrigo New York, Inc.

  • Jonakayem Pharma Formulation Pvt. Ltd.

  • Glenmark Generics Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • Fougera Pharmaceuticals Inc.

  • Eli Lilly Company